Search

    FILTERS

    Services

    Languages

    Location

    17 Doctors

    Vicky QI, MD, PhD

    Department:
    Medical Oncology
    Palliative Care
    Cancer Gentics Clinic
    Medical Oncology(Solid Tumor)
    Cancer Center (Follow-up Consultation Only)
    Cancer MDT Clinic
    Location:
    Jiahui International Hospital (Shanghai)
    Languages:
    普通话,  English
    Doctor's bio

    Dr. Vicky QI is the Associate Chief Physician and an oncologist at Jiahui International Cancer Center. Dr. QI specializes in the diagnosis and treatment of malignant solid tumors, with expertise in comprehensive medical oncology care for lung cancer, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, bile duct cancer, gallbladder cancer, pancreatic cancer, esophageal cancer, gynecological tumors, and head and neck tumors. She is also skilled in the symptom management of cancer patients. Particularly in lung cancer, Dr. Qi has extensive clinical experience in advanced diagnostic techniques, including bronchoscopy, CT-guided lung biopsy. Additionally, she is proficient in cancer genetic screening, cancer pain management, nutritional support for cancer patients, palliative care, and whole-course management of cancer patients, and is able to give humanistic and psychological care to cancer patients and their family members.
    Dr. Qi graduated from Shanghai Jiaotong University School of Medicine in 2012 with master’s degree in Respiratory Medicine, and earned her Ph.D. in Oncology in 2017 from Tongji University School of Medicine. During 2015 and 2016, she worked at M.D. Anderson Cancer Center as a visiting scientist. Before joining Jiahui Health, Dr. Qi served as an Associate Chief Physician in the Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University. Dr. Qi specializes in diagnosis and treatment of solid tumor, especially lung cancer. She also performed the operation of bronchoscopy and CT-guided transthoracic percutaneous fine needle aspiration and core biopsy.
    As for scientific research, Dr. Qi has participated in several international and domestic multi-center clinical trials for anti-cancer drugs. She has presided over youth fund of national natural science foundation of China (NSFC) and has been involved in the research of drug resistance in lung cancer. As the first author, she has published more than 10 peer-reviewed papers in SCI Journals.

    Read More

    WANG Bin, MD,PhD

    Department:
    BNCT Consultation
    Radiotherapy induced skin reactions clinic
    Radiation Oncology
    Cancer Center (Follow-up Consultation Only)
    Location:
    Jiahui International Hospital (Shanghai)
    Languages:
    普通话,  English
    Doctor's bio

    Dr. WANG Bin serves as a radiation oncologist of Jiahui International Cancer Center. Dr. Wang obtained the bachelor degree of Clinical Medicine from Zhengzhou University School of Medicine in 1999, and then he received the master degree in medical oncology and Ph.D. in pathology at Shanghai Secondary Millitary University. Before joining Jiahui Health, he served as attending physician in the Center of Clinical Oncology, Shenzhen Hospital, Hong Kong University and Department of Radiation at a private cancer center in Shanghai. In 2018, he visited the Cancer Center of Queen Mary Hospital, Hong Kong University and Pamela Youde Nethersole Eastern Hospital. Being a radiation oncologist for more than ten years, he specializes in conventional radiation therapy and stereotactic radiotherapy of various tumors, especially the treatment of gastrointestinal, breast, and head & neck cancers. In addition, he also pays close attention to the cardiac toxicity during breast cancer radiotherapy.


    Dr. Wang joined as sub-investigators in a global multi-center clinical trials for liver cancer radiotherapy and a HCC basic research supported by National Natural Science Foundation of China.


    He had several academic publications. He had participated in the translation of the English version of Proton Therapy by MDACC and Target Volume Delineation for Conformal and Intensity-Modulated Radiation Therapy by Nancy Y. Lee.
    Dr. Wang is a current member of Chinese Society of Clinical Oncology (CSCO).

    Read More

    WANG Liwei

    Department:
    Medical Oncology(Solid Tumor)
    Location:
    Jiahui International Hospital (Shanghai)
    Languages:
    普通话,  English
    Doctor's bio

    Current Positions
    •Chief Physician, Professor, Doctoral Supervisor
    •Director of Medical Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine
    •Director, MDT Expert Committee, Renji Hospital
    •MDT Team Leader for Cancers of Unknown Primary Origin & Multiple Primary Malignancies, Renji Hospital
    •Director, Shanghai Jiao Tong University Pancreatic Cancer Diagnosis and Treatment Center
    •Director, Oncology Clinical Drug Trial Base
    •Consultant of Jiahui International Cancer Center

    Clinical Expertise & Research Focus
    •Personalized precision diagnosis and treatment of various complex and difficult tumors
    •Translational research on gastrointestinal tumors, especially pancreatic cancer precision diagnosis and treatment
    •Oncology multidisciplinary team (MDT) diagnosis and treatment
    •Individualized targeted therapy and immunotherapy guided by clinical tumor genomics
    •Special expertise in precision treatment models for cancers of unknown primary and multiple primary tumors

    Academic Appointments
    •Head, Pancreatic Tumor Group, Chinese Society of Oncology, Chinese Medical Association
    •Council Member, Chinese Society of Clinical Oncology (CSCO)
    •First Director, CSCO Pancreatic Cancer Expert Committee
    •Council Member, China Anti-Cancer Association (CACA), and First Director, CACA Integrated Onco-Nephrology Committee
    •Council Member, Shanghai Medical Association; Director, Oncology Internal Medicine Branch
    •Vice Chairman, Shanghai Anti-Cancer Association; Director, Difficult Tumor Professional Committee
    •President, Yangtze River Delta Cancer Specialty Alliance
    •Leading Talent of Shanghai; Outstanding Academic Leader of Shanghai

    Research Achievements
    •Visiting researcher at UCLA and MD Anderson Cancer Center (2001–2004)
    •Led development of China’s first Chinese Expert Consensus on Comprehensive Diagnosis and Treatment of Pancreatic Cancer
    •Led development of the first CSCO Pancreatic Cancer Diagnosis and Treatment Guidelines
    •Led development of the first CACA Technical Guidelines for the Protection of Cancer-Related Kidney Diseases
    •Principal Investigator of 7 National Natural Science Foundation of China (NSFC) projects, including major research plans
    •Principal Investigator of 2 major new drug creation projects and over 10 other fund projects
    •Founded China’s first “Pancreatic Cancer Internet+ Consultation Platform” and “China Advanced Pancreatic Cancer Registry Platform”
    •Published over 100 SCI-indexed papers with over 1,000 citations
    •Associate Editor, Journal of Pancreatology; Editorial Board Member, Cancer Research, Journal of Hematology & Oncology (JHO), etc. 

    Read More

    HAN Baohui

    Department:
    Medical Oncology(Solid Tumor)
    Location:
    Jiahui International Hospital (Shanghai)
    Languages:
    普通话,  English
    Doctor's bio

    Professional Summary
    Professor HAN Baohui has spent several decades in respiratory medicine clinical practice, teaching, and translational research, focusing on lung cancer multidisciplinary comprehensive care and novel biotherapy / targeted / anti-angiogenic strategies (including immune chemotherapy clinical exploration).
    He is a State Council Special Allowance recipient and has led or co authored national level lung cancer guidance/consensus, e.g. the Chinese Expert Consensus on Anti angiogenic Drug Therapy for Advanced NSCLC, and has contributed to CMA/NCCN style guideline work referenced in Chinese scholarly publications.

    Position & Affiliations
    •Senior Consultant, Lung Cancer MDT Team, Jiahui International Cancer Center
    •Emeritus Director, Dept. of Pulmonary and Critical Care Medicine, Shanghai Chest Hospital
    •Professor / Doctoral Supervisor, Shanghai Jiao Tong University School of Medicine
    •Consultant of Jiahui International Cancer Center
    Clinical Expertise
    •Complex/high risk lung cancer diagnosis and treatment
    •Targeted therapy & resistance pathways, with ongoing work in EGFR Exon20ins and novel agent development
    •Biotherapy/immunotherapy + anti angiogenic combinations, including clinical trial–based care pathways

    Key Research & Drug Development Role
    •Principal Investigator (PI) for several pivotal clinical studies supporting Furmonertinib (伏美替尼) and other domestically developed anti cancer agents; he is especially active in EGFR exon 20 insertion (Exon20ins) and broader targeted + immunotherapy combination pathways for advanced NSCLC.
    •Longstanding leadership in drug clinical trial infrastructure: Director of Shanghai Chest Hospital’s Drug Clinical Trial Institution / GCP center; NMPA (formerly CFDA) review/expert panel roles in related contexts.

    Professional & Society Appointments
    •Member, International Association for the Study of Lung Cancer(IASLC)
    •Member, American Society of Clinical Oncology(ASCO)
    •Executive President / Executive Chair, Chinese Academy of Lung Cancer
    •Executive Committee Member, Chinese Society of Clinical Oncology(CSCO)
    •Vice Chair, CSCO NSCLC Committee
    •Standing Committee Member, Chinese Medical Association (CMA) Cancer Committee
    •National Medical Products Administration (NMPA)review/assessment expert

    Read More

    GUO Ye

    Department:
    Medical Oncology(Solid Tumor)
    Location:
    Jiahui International Hospital (Shanghai)
    Languages:
    普通话,  English
    Doctor's bio

    Chief Physician; Deputy Chief of the Department of Oncology Medicine and Director of the Phase I Clinical Trial Center, East Hospital Affiliated to Tongji University
    Consultant of Jiahui International Cancer Center

    Prof. GUO Ye graduated from Shanghai Medical University in 1996 and obtained a Master's degree in Oncology from the Graduate School of Fudan University in 2003. In 2006, he completed systematic Clinical Fellow training in the Department of Medical Oncology-Hematology at the National University Hospital, Singapore. Prof. GUO worked in the Department of Medical Oncology at Fudan University Shanghai Cancer Center from 1996 to 2017, and since 2017 has been at Shanghai East Hospital, serving as Deputy Chief of the Department of Oncology Medicine and Director of the Phase I Clinical Trial Center. He has published more than 20 papers in SCI-indexed journals.

    Clinical Expertise
    Medical treatment of head and neck cancers
    Medical treatment of lymphoma

    Academic Appointments
    Deputy Secretary-General, Chinese Society of Clinical Oncology (CSCO)
    Chairman, Head and Neck Cancer Committee, Chinese Society of Clinical Oncology (CSCO)
    Vice Chairman, Thyroid Cancer Committee, Chinese Society of Clinical Oncology (CSCO)
    Vice Chairman, Head and Neck Cancer Committee, Chinese Medical Doctor Association
    Standing Committee Member, Lymphoma Alliance, Chinese Society of Clinical Oncology (CSCO)
    Vice Chairman, Youth Committee, Tumor Chemotherapy Committee, China Anti-Cancer Association
    Member, Head and Neck Cancer Committee, China Anti-Cancer Association
    Member, Nasopharyngeal Cancer Committee, China Anti-Cancer Association
    Member, Lymphoma Committee, China Anti-Cancer Association
    Vice Chairman, Head and Neck Cancer Committee, Shanghai Anti-Cancer Association
    Vice Chairman, Lymphoma Committee, Shanghai Anti-Cancer Association

    Read More

    CHEN Jie

    Department:
    Medical Oncology(Solid Tumor)
    Location:
    Jiahui International Hospital (Shanghai)
    Languages:
    普通话,  English
    Doctor's bio

    Director of Neuroendocrine Tumor Center and Director of Department of Neuroendocrine Tumor, Fudan University Shanghai Cancer Center; Chief Physician, Professor, Doctoral Supervisor; Chief Expert, Neuroendocrine Tumor Multidisciplinary Team
    Consultant of Jiahui International Cancer Center

    Education
    Graduated from West China University of Medical Sciences, School of Clinical Medicine, in 1994
    Twice a visiting scholar at the Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, during postgraduate studies (2000–2002)
    Received MD in Gastroenterology from the First Affiliated Hospital of Sun Yat-sen University in 2002
    Postdoctoral research at the Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Magdeburg, Germany (2002–2004), focusing on the pathogenesis of gastrointestinal tumors
    Studied neuroendocrine tumor diagnosis and treatment at Churchill Hospital, University of Oxford, and Royal Free Hospital / King's College Hospital, University of London (November–December 2011)

    Clinical Expertise
    Diagnosis and treatment of various neuroendocrine tumors, including:
    -Neuroendocrine tumors of various sites and types: gastric and intestinal NETs, pancreatic NETs, gastrinoma, insulinoma, glucagonoma, carcinoid syndrome, ACTHoma, VIPoma, carcinoid, atypical carcinoid, small cell carcinoma, large cell neuroendocrine carcinoma, pheochromocytoma, paraganglioma, medullary thyroid carcinoma, cutaneous Merkel cell carcinoma, etc.
    -Hereditary neuroendocrine tumors: multiple endocrine neoplasia types 1, 2 and 4 (MEN1/2/4), von Hippel-Lindau (VHL) syndrome, neurofibromatosis type 1 (NF1), etc.

    Academic Contributions & Appointments
    Since 2010, pioneered the field of neuroendocrine tumors (NEN) in China and established a comprehensive clinical diagnosis and treatment system, including a multidisciplinary team covering all NEN-related disciplines, dedicated medical groups, wards and clinics, with an annual outpatient volume of 4,500 visits
    Selected in 2015 as the only Asian member of the ENETS Advisory Board, European Neuroendocrine Tumor Society
    In 2015, the Chinese Study Group for Neuroendocrine Tumor (CSNET) under the Pancreatic Cancer Committee of China Anti-Cancer Association was established, and she served as its first group leader
    Invited in 2019 as an editorial board member of Neuroendocrinology, the official journal of ENETS
    Invited in 2020 as a member of the Medical Advisory Board of the International Neuroendocrine Cancer Alliance (INCA)
    Invited in 2021 as a member of the Neuroendocrine and Endocrine Tumors Group of the European Society for Medical Oncology (ESMO), the first and only Chinese expert to serve on this committee
    Initiated the establishment of the Neuroendocrine Tumor Committee of the China Anti-Cancer Association in 2022 and will serve as its first chairman
    Member, Chinese Medical Association
    Vice Chairman, Tumor Endocrinology Committee, China Anti-Cancer Association
    Deputy Head, Gastrointestinal Hormone and Neuroendocrine Tumor Group, Digestive Disease Branch, Chinese Medical Association
    Vice Chairman, Pancreatic Neuroendocrine Tumor Committee, Pancreatic Disease Branch, Chinese Medical Doctor Association
    Standing Committee Member, Neuroendocrine Tumor Branch, China International Exchange and Promotive Association for Medical and Health Care
    Member, Rare Tumor Expert Committee, Chinese Society of Clinical Oncology (CSCO)
    Senior Editorial Board Member, Journal of Neuroendocrinology; Editorial Board Member, Journal of Pancreatology; Editorial Board Member, China Oncology; Corresponding Editorial Board Member, Chinese Journal of Digestion

    Research Achievements
    Published more than 40 SCI-indexed clinical research papers, over 30 as corresponding author or co-corresponding/first author, covering epidemiology, molecular markers, drug therapy, imaging diagnosis, and pathological grading and staging
    A multicenter collaborative study on modified staging of pancreatic neuroendocrine tumors was published in the top oncology journal J Clin Oncol
    As CSNET group leader, initiated and participated in the development of two CSNET expert consensuses, published in Int J Oncol in 2016–2017
    As a major contributor, participated in the development of the Expert Consensus on Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Tumors (Digestive Disease Branch, Chinese Medical Association) and the Guidelines for Diagnosis and Treatment of Pancreatic Neuroendocrine Tumors (Pancreatic Surgery Group, Surgery Branch, Chinese Medical Association)
    As chief editor, led the development of the first Integrated Diagnosis and Treatment Guidelines for Neuroendocrine Tumors of the China Anti-Cancer Association
    As a member of the ENETS Advisory Board, participated in the development of the 2017 updated ENETS clinical practice guidelines for neuroendocrine tumors

    Read More

    HU Chaosu(Specialist), MD

    Department:
    Radiation Oncology
    Oral and Maxillofacial Surgery
    Tongue & Parotid gland
    Location:
    Jiahui International Hospital (Shanghai)
    Languages:
    普通话,  English
    Doctor's bio

    HU Chaosu, M.D., is a Professor, Chief Physician, and Doctoral Supervisor. He currently serves as the Director of the Nasopharyngeal Carcinoma Diagnosis and Treatment Center at Fudan University and is the Chief Expert in Nasopharyngeal Carcinoma.

    Professor HU is a leading authority in the field of radiotherapy for head and neck tumors in China, with over 30 years clinical expertise in precision radiotherapy, comprehensive treatment, immunotherapy, and targeted therapy for nasopharyngeal carcinoma.

    He holds several prestigious positions, including:
    -Honorary Chairman of the Nasopharyngeal Carcinoma Professional Committee of the Chinese Anti-Cancer Association
    -Chairman of the Nasopharyngeal Carcinoma Quality Control Expert Committee of the National Cancer Center
    -Standing Committee Member of the Nasopharyngeal Carcinoma Professional Committee of the Chinese Society of Clinical Oncology (CSCO)
    -Chairman of the Head and Neck Tumor Professional Committee of CSCO
    -Standing Committee Member of the Head and Neck Tumor Professional Committee of the Chinese Anti-Cancer Association
    -Standing Committee Member of the Neuro-Oncology Professional Committee of the Chinese Anti-Cancer Association
    -Honorary Chairman of the Radiation Oncology Committee of the Shanghai Medical Association
    -Honorary Chairman of the Nasopharyngeal Carcinoma Professional Committee of the Shanghai Anti-Cancer Association

    Additionally, he serves as an editorial board member for several academic journals, including Chinese Journal of Radiation Oncology, Cancer, and China Oncology, and is a peer reviewer for multiple international journals.

    Read More

    XUAN Linli, MD

    Department:
    Palliative Care
    Cancer Gentics Clinic
    Medical Oncology(Solid Tumor)
    Medical Oncology (Hematology)
    CART Therapy and Stem Cell Transplantation
    Cancer MDT Clinic
    Lymphoma Clinic
    Leukemia Clinic
    Multiple Myeloma Clinic
    MDS and MPN Clinic
    Location:
    Jiahui International Hospital (Shanghai)
    Languages:
    普通话,  English
    Doctor's bio
    Dr. XUAN Linli is currently Chief of Medical Oncology at Jiahui International Cancer Center (JICC). With over 30 years of experience in cancer research and clinical practice, Dr. XUAN possesses extensive expertise in diagnosis and treatment of hematologic and oncologic illness, including cancer risk assessment and reduction.


    After 6 years of study in Shanghai Medical University, Dr. XUAN furthered her clinical training in the Hematology Division of the Internal Medicine Department at Huashan Hospital Fudan University, under the guidance of Professor DING Xunjie, one of the founding figures of the Hematology Department at Huashan Hospital and a key authority in hematology nationwide. Then in the US, she spent an additional 6 years in residency and fellowship training, including specialization in medical oncology and hematology at the University Hospitals, Case Western Reserve University in Cleveland Ohio. Before joining Jiahui Health, Dr. XUAN practiced medical oncology and hematology in the U.S. for over two decades. She obtained certifications from the American Board of Internal Medicine (ABIM) in Internal Medicine, Medical Oncology, and Hematology. Dr. XUAN is also a member of the American Society of Clinical Oncology (ASCO).


    With a solid academic foundation, systematic training in both China and the U.S., and years of clinical experience in patient care, Dr. XUAN is well-versed in internationally advanced technologies for cancer prevention, diagnosis, and treatment. She is skilled in managing a variety of oncological and hematological diseases. She has extensive experience in CAR-T therapy and post-infusion management for both hematologic malignancies and solid tumors, and served as the attending physician for the first foreign patient receiving solid tumor CAR-T therapy in China, demonstrating her outstanding capability in cutting-edge immunotherapy.


    She prioritizes patients' quality of life and is adept at alleviating suffering through standardized, internationally recognized personalized treatment plans and symptom management.


    Dr. XUAN’s areas of expertise in hematology and oncology treatment include but not limited to:


    - Diagnosis and treatment of solid tumors, particularly all stages of breast cancer, advanced gynecological malignancies, advanced prostate cancer and other urological cancer, colorectal cancer, esophageal and stomach cancer, lung cancer, skin cancers especially melanoma, etc.


    - Diagnosis and treatment of hematologic malignancies, especially multiple myeloma and lymphoma, chronic lymphocytic leukemia, myeloproliferative neoplasms.


    - CAR-T cell therapy (for both hematologic and solid tumors) and comprehensive post-infusion management;


    - Diagnosis and treatment of other hematologic conditions, including anticoagulation therapy, platelet disorder, myelodysplastic syndromes and all causes of anemia.


    - Cancer genetics, including cancer risk assessment and risk reduction,


    - Palliative care, including pain management and supportive therapy.

    Read More

    HAO Siguo, MD, PhD

    Department:
    Medical Oncology
    Platelet Disorders Clinic
    Hematology
    Leukopenia Clinic
    Medical Oncology (Hematology)
    Bleeding and Coagulation Clinic
    Serum Globulin Abnormality Clinic
    CART Therapy and Stem Cell Transplantation
    Anemia Clinic
    Lymphoma Clinic
    Leukemia Clinic
    Multiple Myeloma Clinic
    MDS and MPN Clinic
    Location:
    Jiahui International Hospital (Shanghai)
    Languages:
    普通话,  English
    Doctor's bio

    HAO Siguo, MD, PhD, is currently Chief of Hematology at Jiahui International Hospital. He’s also the Director and Academic Leader of the Department of Hematology at Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine. He also serves as Chief Physician, Professor, Doctoral and Postdoctoral Supervisor.

    Dr. HAO earned his Ph.D. in Hematology in 2003 from Shanghai Second Medical University and the Shanghai Institute of Hematology. In 2000, he conducted advanced clinical training in hematopoietic stem cell transplantation (HSCT) as a visiting scholar at the Blood Center of Singapore General Hospital. From 2004 to 2007, he pursued postdoctoral research in tumor immunotherapy in Canada, focusing on translational applications in hematologic malignancies

    Dr. HAO has almost 40 years of medical practicing experience. He specializes in the treatment of difficult and complicated hematological diseases, such as acute/chronic leukemia, malignant lymphoma, multiple myeloma, myelodysplastic syndrome (MDS), aplastic anemia, and anemia, thrombocytopenia caused by various reasons.

    Dr. HAO has made outstanding achievements in the field of cellular immunotherapy. Since 2017, he has pioneered CAR-T cell therapy for lymphoma and multiple myeloma, accumulating extensive experience in clinical practice, particularly in managing complex and high-risk cases. He demonstrates exceptional therapeutic capabilities in challenging situations including extramedullary lesions, severe comorbidities, elderly patients, or relapsed/refractory cases after multiple lines of therapy, enabling him to develop individualized treatment plans and meticulously manage treatment-related adverse events. To date, numerous patients with complex conditions have achieved deep remission through his CAR-T treatments, with the longest disease-free survival exceeding 8 years, confirming the long-term effectiveness of his therapeutic strategies. He led a groundbreaking clinical study on CAR-T cell therapy for multiple myeloma, achieving remarkable efficacy and safety outcomes. This research was selected for oral presentations at the American Society of Hematology (ASH) Annual Meeting and the International Myeloma Working Group (IMWG) conference on multiple occasions, with the findings published in Haematologica, a top-tier hematology journal. Based on this clinical trial, "Zevor-cel" (also known as CT053) was approved by China's National Medical Products Administration (NMPA, formerly SFDA) in June 2023, becoming a widely accessible cellular therapy for patients.

    Additionally, Dr. Hao has profound expertise in hematopoietic stem cell transplantation (HSCT), specializing in both autologous and allogeneic transplants (including haploidentical and umbilical cord blood transplantation). Under his leadership, Xinhua Hospital's Department of Hematology has become one of the few facilities in Shanghai performing cord blood transplants for adult malignant hematologic diseases, successfully treating nearly 100 patients with the longest disease-free survival exceeding 12 years.

    Dr. HAO serves as the Vice Chairman of the 10th and 11th Shanghai Hematology Society of Chinese Medical Association, the Vice Chairman of Hematology and Oncology Branch of Shanghai Anti-Cancer Association, the member of Hematology Branch of Chinese Geriatrics Society, the member of Cord Blood Application Committee of Chinese Maternal and Child Health Association, the Vice President of Shanghai Hematopoietic Stem Cell Transplantation Alliance, the Standing Committee member of Hematology Branch of Shanghai Traditional Chinese and Western Medicine Association, the member of Expert Committee of Chinese Stem Cell Bank, the Deputy Director of Shanghai Institute of Hematology, and the member of Hematology Branch of Shanghai Immunology Society. He has undertaken and completed several provincial and ministerial scientific research projects including projects funded by National Natural Science Foundation. Dr. HAO has published more than 100 academic papers, including more than 50 SCI papers. He has presided over 4 National Natural Science Foundation projects. He has also presided several research projects of Shanghai Science and Technology Commission, Health Commission and Shanghai Shenkang Hospital Development Center. Dr. HAO also has been in charge of multiple clinical research projects. He chaired the BCMA CAR-T cell therapy for R/R multiple myeloma program, which has been communicated in several oral presentations at international congresses such as IMWG, ASH, etc., and the results of his research have also been published in the journal Haematologica 2023.

    Read More

    XUE Peng, MD, PhD

    Department:
    Palliative Care
    Genetic counseling
    Cancer Gentics Clinic
    Medical Oncology(Solid Tumor)
    Port-A-Cath Clinic
    Cancer MDT Clinic
    Location:
    Jiahui International Hospital (Shanghai)
    Languages:
    普通话,  English,  日本語
    Doctor's bio

    Dr. XUE Peng is the Associate Chief Physician and the Assistant to Chief of Medical Oncology at Jiahui International Cancer Center. Dr. XUE specializes in the comprehensive management of malignant solid tumors, utilizing advanced treatment modalities such as chemotherapy, targeted therapy, immunotherapy, and PORT implantation. His expertise covers a wide range of common solid tumors, including gastrointestinal, pancreatic, breast, lung, genitourinary, and gynecological cancers, as well as rare tumor types. Additionally, he places a strong emphasis on the symptomatic care of cancer patients, with extensive clinical experience in managing cancer-related pain, preventing and treating chemotherapy-induced nausea and vomiting (CINV), and providing palliative care.
    Dr. XUE graduated from Shanghai Second Medical University with Bachelor degree in 2000. He then spent three years conducting research at the State Key Laboratory of Oncogenes and Related Genes at Shanghai Cancer Institute (2000–2003). In 2006, he achieved Master degree in Medical Oncology at Shanghai Jiaotong University School of Medicine. Before joining Jiahui Health, Dr. XUE had worked for many years in the Medical Oncology Department of Shanghai General Hospital since 2006, and obtained his Ph.D. degree in Medical Oncology during the work. Dr. XUE was awarded the Sasagawa Fellowship for academic funding and participated in pancreatic cancer research as a visiting scholar in Kyoto University Hospital in Japan from 2012 to 2013. He has published several peer-reviewed papers in the field of chemotherapy for pancreatic cancer patients.
    He is currently a member of Chinese Society of Clinical Oncology and Japan-china Medical Association.

    Read More

    CONTACT US

    Follow us

    Jiahui's Partners

    Copyright © 2017 by Jiahui,Inc. All rights reserved 沪ICP备15019023号-1 | 沪公网安备 31010402004841 号

    2021-06-01
    • Scan the QR code to follow
      Expat account Jiahui Health